Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Abstract
The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
Claims
exact text as granted — not AI-modified1 - 36 . (canceled)
37 . A pharmaceutical composition comprising at least one carbostyril derivative selected from the group consisting of DM-1458, DM-1454, and DCPP in combination with at least one serotonin reuptake inhibitor.
38 . The composition of claim 37 , wherein at least one serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram, and salts thereof.
39 . The composition of claim 38 , wherein at least one serotonin reuptake inhibitor is citalopram.
40 . The composition of claim 37 , further comprising at least one pharmaceutically acceptable carrier.
41 . The composition of any one of claims 37 to 40 being useful for treatment of mood disorders.
42 . The composition of claim 41 wherein the mood disorder is depression or major depressive disorder.
43 . The composition of claim 42 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.
44 . The composition of any one of claims 37 to 40 being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.Join the waitlist — get patent alerts
Track US2019151308A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.